Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
about
Lung cancer in never smokersIn Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung CancerBenchmarking of mutation diagnostics in clinical lung cancer specimensGeneration of a non-small cell lung cancer transcriptome microarrayLaser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild typeAlterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Relationship between EGFR expression, copy number and mutation in lung adenocarcinomasMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyInvestigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression.Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIsIncreased ALK gene copy number and amplification are frequent in non-small cell lung cancerEGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment.Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersMiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.Pathogenesis of lung cancer signalling pathways: roadmap for therapies.Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis.Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.A high-content image analysis approach for quantitative measurements of chemosensitivity in patient-derived tumor microtissues.ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomasAnalysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer.The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics.Making a difference with teamwork.The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI.Role of long non-coding RNA in drug resistance in non-small cell lung cancer.Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer.
P2860
Q28386853-9B9F47C2-C00C-43CC-A4D2-344D82260DFCQ28551308-5D2DBA12-2D4A-4F8B-8BB4-4675892279F8Q28740430-6B5CAE96-D6A9-47DF-93F0-494F49783BCFQ33338999-B8FE6FDB-F2AA-47CB-893D-F7701D70CAF7Q33358603-4F307152-8A44-46EE-96FA-02D29C581003Q33411775-7DC867BA-BA3C-45D1-BA78-C5997E71D2B9Q33634703-EB897569-324D-4AED-99B6-9144F45C4115Q33828409-A8592425-11D7-4B82-8AE2-64A3D6EA617FQ33844140-B7F5EFD8-8172-407F-B1BC-153648E230D2Q34589493-8A4AA371-92A4-4CAD-93CA-587BC6824610Q35187806-13404ED1-003E-4ECE-A2A7-D98765CA3056Q35471961-666A7315-49C3-43C5-AB71-264935034D58Q35872687-99707443-78CF-4A3D-BF0F-8643166D94FFQ35897794-615656F2-55FB-4CB0-B29A-6190EE2DA695Q35983929-B435758A-FC52-4831-AAFE-37ED725C855DQ36048238-4CAB0808-0B11-4FD9-88BA-22086CC78668Q36085487-2D184617-6CB9-4C00-ABE5-847637CF7776Q36470768-16F4898E-AD61-4119-858E-7CD483EFD982Q36485352-1BF07CBA-E181-4080-B0DC-9B5DC9D77458Q36696463-D3D32DAA-D0D2-4E8E-BDA2-FEE601FC0273Q36839768-7A5826FC-C0D2-4F2A-8243-A532A13001EBQ36905639-ACF2914E-D749-4357-9A1A-DEF00086F04BQ37274389-107B254C-6AAD-4591-9749-F5DB1F85E007Q37389526-6E036AC8-C706-434B-8B22-EAEEA01821BFQ37630180-8F48C6C8-FC89-457A-9D1B-3DFB4E088FA7Q37659062-772DCFE7-0FA9-4F22-A1D2-57AF6EE655CDQ37721218-54A12C5E-959B-4664-84AD-53F6582107BEQ38410994-4BCDB011-2BE8-40D8-BBD1-91966B5DD6F1Q38526025-D0E41330-BA77-4136-B308-F9E1238CDD24Q38659180-D215CE52-7D81-4525-8BFC-AF657002B533Q38919117-80FB81D7-71E5-43B0-AE99-F87ACF1410C7Q39308117-4FDEB72D-AF51-4288-954F-1FD03301E6E3Q39819733-204B3709-24E3-4B47-90A2-20B1379C3554Q40808623-DE6B200E-9106-4FF6-B0CC-7D5B7EF3E0CCQ43128868-5E2BAEFE-D025-47BA-83D0-D2A7B872B1D3Q43199022-10DC1D4B-DC12-4F60-A5C7-86A58737F97EQ46070125-4D044CFD-D233-4731-B8EF-074E1A79160CQ50050305-3C02048C-9604-4BF6-A105-0ED58397443DQ53687949-5E463014-5BD9-4E7E-92EE-84D9D40303B8Q54344522-CC01EC87-0217-43E7-8146-75908E840556
P2860
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@ast
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@en
type
label
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@ast
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@en
prefLabel
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@ast
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@en
P2860
P921
P356
P1476
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
@en
P2093
T Mitsudomi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603665
P407
P577
2007-02-27T00:00:00Z
2007-03-26T00:00:00Z